Learn More
Invitrogen™ Cripto Polyclonal Antibody

Description
In Western blot a band is seen at ~18 kDa representing the core form of Cripto1, and at ~36 kDa reporesenting the glycosylated/ post-translationally modified form. Suggested positive control: MDA-MB231 (human breast cancer) lysates.
Specifications
Specifications
| Antigen | Cripto |
| Applications | Flow Cytometry, Western Blot, Immunocytochemistry |
| Classification | Polyclonal |
| Concentration | 1.0 mg/mL |
| Conjugate | Unconjugated |
| Formulation | PBS with 0.02% sodium azide |
| Gene | TDGF1 |
| Gene Accession No. | P13385, P51865 |
| Gene Alias | CR; CR1; CRGF; CRIPTO; cripto growth factor; Cripto-1; cripto-1 growth factor; Cripto-3; epidermal growth factor-like Cripto protein; epidermal growth factor-like cripto protein CR1; Tdgf1; TDGF2; teratocarcinoma-derived growth factor; teratocarcinoma-derived growth factor 1; TERATOCARCINOMA-DERIVED GROWTH FACTOR PRECURSOR (EPIDERMAL GROWTH FACTOR-LIKE CRIPTO PROTEIN) (CRIPTO GROWTH FACTOR) |
| Gene Symbols | TDGF1 |
| Show More |
Safety and Handling
By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.